)
Biogen (BIIB) investor relations material
Biogen M&A announcement summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Deal rationale and strategic fit
Acquisition targets two best-in-class, FDA-approved commercialized medicines in immunology and rare diseases, expanding the growth portfolio and accelerating entry into nephrology.
Focus on assets post-phase III or early in launch to minimize risk and drive near- and long-term growth.
Strategic fit aligns with expansion beyond neuroscience into immunology and rare diseases, leveraging existing and new capabilities and U.S. nephrology infrastructure.
Acquisition provides a commercial presence in nephrology and transplant centers, supporting future launches like felzartamab.
Combines commercialization capabilities to maximize product potential and reach more patients.
Financial terms and conditions
Purchase price is $41 per share, totaling approximately $5.6 billion in cash, with contingent value rights (CVRs) up to $4 per share tied to SYFOVRE sales milestones between 2027 and 2031.
Financed through $3.6 billion cash on hand, $2 billion from revolving credit and bank loans, with plans to fully de-lever by end of 2027.
Represents an 86% premium to the 90-day average stock price and a 35% premium to the 52-week high.
Transaction expected to close in Q2 2026, subject to customary conditions and regulatory approvals.
Revenue from acquired products projected to grow in the mid- to high teens for at least the next two years, with combined 2025 net sales of $689 million.
Synergies and expected cost savings
Combined commercial and nephrology infrastructure enables faster and more effective launches, especially for felzartamab.
Opportunity to leverage both companies’ sales and marketing strengths to improve patient activation and retention.
Expected to generate a meaningful increase in non-GAAP EPS CAGR through the end of the decade, with accretion starting in 2027.
Potential for cost discipline and rationalization of operating expenses post-close.
- Advances in Alzheimer's, SMA, and immunology pipelines highlight innovation and pivotal trials.BIIB
Stifel 2026 Virtual CNS Forum18 Mar 2026 - Felzartamab targets four kidney indications with phase III trials and a $2B+ AMR market opportunity.BIIB
Leerink Global Healthcare Conference 202610 Mar 2026 - Pipeline expansion and new launches drive growth, with major Alzheimer's and SMA catalysts ahead.BIIB
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Late-stage lupus therapies and a diverse immunology pipeline target major unmet needs.BIIB
Piper Sandler Virtual Novel Targets in Immunology Symposium13 Feb 2026 - Growth products rose 19% to $3.3B in 2025, offsetting MS declines and driving 2% revenue growth.BIIB
Q4 20256 Feb 2026 - All proposals passed, with a focus on growth, portfolio diversification, and governance.BIIB
AGM 20243 Feb 2026 - Q2 Non-GAAP EPS up 31% YoY; guidance raised as rare disease and new launches drive growth.BIIB
Q2 20242 Feb 2026 - Growth strategy advances with strong launches, expanded access, and focus on margin improvement.BIIB
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Steady LEQEMBI growth, sub-Q advances, SKYCLARIS expansion, and pipeline diversification drive outlook.BIIB
Jefferies Global Healthcare Conference1 Feb 2026
Next Biogen earnings date
Next Biogen earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage